InnovAge (NASDAQ:INNV – Get Free Report) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday, Zacks reports.
Other equities analysts also recently issued research reports about the company. Weiss Ratings upgraded InnovAge from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. Wall Street Zen upgraded InnovAge from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Finally, KeyCorp boosted their price objective on InnovAge from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.50.
Check Out Our Latest Analysis on InnovAge
InnovAge Trading Down 1.7%
Shares of InnovAge stock opened at $9.42 on Monday. The firm has a 50-day simple moving average of $9.46 and a two-hundred day simple moving average of $9.25. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.16 and a current ratio of 1.16. InnovAge has a fifty-two week low of $4.70 and a fifty-two week high of $12.64. The company has a market cap of $1.29 billion, a P/E ratio of 159.67 and a beta of 0.16.
InnovAge (NASDAQ:INNV – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. InnovAge had a return on equity of 3.63% and a net margin of 0.88%. The firm had revenue of $264.76 million for the quarter, compared to analysts’ expectations of $257.23 million. As a group, equities analysts predict that InnovAge will post 0.44 earnings per share for the current fiscal year.
Insider Activity
In other news, major shareholder Carson Anderson & Stow Welsh sold 1,500,000 shares of InnovAge stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $9.25, for a total value of $13,875,000.00. Following the sale, the insider owned 101,076,555 shares in the company, valued at $934,958,133.75. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Nicole Damato sold 3,402 shares of the business’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $9.51, for a total transaction of $32,353.02. Following the sale, the insider directly owned 301,495 shares of the company’s stock, valued at $2,867,217.45. This represents a 1.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,027,216 shares of company stock worth $120,489,535 over the last 90 days. 1.10% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On InnovAge
Several institutional investors have recently bought and sold shares of INNV. BlackRock Inc. purchased a new stake in InnovAge during the 2nd quarter worth approximately $17,652,000. Algert Global LLC raised its holdings in shares of InnovAge by 844.1% during the second quarter. Algert Global LLC now owns 630,520 shares of the company’s stock valued at $7,472,000 after acquiring an additional 563,735 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of InnovAge by 207.1% in the third quarter. Goldman Sachs Group Inc. now owns 668,219 shares of the company’s stock valued at $5,880,000 after acquiring an additional 450,610 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of InnovAge in the first quarter valued at approximately $3,349,000. Finally, Marshall Wace LLP acquired a new stake in shares of InnovAge in the third quarter worth approximately $3,589,000. 12.26% of the stock is currently owned by institutional investors and hedge funds.
InnovAge Company Profile
InnovAge, Inc. provides integrated healthcare and social services to older adults through the Program of All-Inclusive Care for the Elderly (PACE). The program serves people who qualify for nursing-home-level care but can continue living in their communities with coordinated support. InnovAge’s services include primary and specialty care coordination, nursing, rehabilitation, social services, prescription medications, transportation, in-home assistance and adult day health services. Care is coordinated by interdisciplinary teams and delivered through a combination of community-based centers and support at home.
See Also
- Five stocks we like better than InnovAge
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.
